$MRNA

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

$VBR dominates $ISCV in scale ($62.3B vs $594.6M) with better liquidity, while $ISCV edges performance (18.3% vs 17.9%) with higher yield.

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.

Moderna settles $2.25B patent dispute, surges 15.99%. Analysis identifies 9 biotech stocks trading 27-65% below fair value with 31-251% upside potential.

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.

Moderna shifts from pandemic revenues toward diversified pipeline including seasonal vaccines and oncology treatments, targeting cash breakeven by 2028 amid FDA progress on flu vaccine candidate.

Large-cap stocks rallied on strong earnings and corporate actions. First Majestic Silver led with 25% gains, joined by Moderna and Global Payments on positive results.

Coatue Management exited CoreWeave with 80% gains, reallocating capital toward a new Moderna position ahead of the biotech stock's 50% rally.

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.

Market volatility creates buying opportunities in AI and biotech leaders Nvidia, Moderna, and Amazon Web Services, each positioned to benefit from industry growth trends.

Tech stocks surge as S&P 500 gains 0.56% on AI infrastructure optimism. Nvidia leads rally following Meta partnership announcement for data center chips.

FDA accepts Moderna's flu vaccine application after prior rejection, setting August priority review date. Stock surges 5.77% as company expands mRNA pipeline beyond COVID-19.

January inflation came in below expectations at 2.4%, hitting eight-month lows. Markets rallied as investors bet on potential Fed rate cuts later this year.